LianBio up on completing enrollment in eye disease drug trial

LianBio

08/06/2023 15:53

** Shares of Asia-focused biopharma co LianBio  LIAN.O  up
2% at $2.51 
    ** Co completes enrollment in late-stage trial studying
Chinese patients with Demodex blepharitis, an eye disease caused
by infestation of ectoparasites called Demodex mites
    ** LIAN says topline results expected in Q4
    ** Currently, there are no treatments approved by the FDA or
China National Medical Products Administration for Demodex
blepharitis
    ** Stock up 53% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))